Real-time prescription benefit transactions are designed to give clinicians essential information on an individual patient’s benefits before writing a prescription, according to Laura Topor, president of Granada Health.
Real-time prescription benefit transactions are designed to give clinicians essential information on an individual patient’s benefits before writing a prescription, according to Laura Topor, president of Granada Health.
Transcript (slightly modified)
What are real-time prescription benefit transactions and what value do they provide?
Real-time benefit transactions are something that the industry is looking at as a way to provide the doctor at the point of prescribing with patient-specific information about their benefits. So, is the product covered? What’s the patient cost going to be? Are there coverage edits or a prior authorization required? Are there any pharmacy restrictions?
Because what’s often happening is they write the prescription, maybe it goes to a pharmacy that can’t fill that product, or the patient gets to the counter and realizes that they can’t afford the hundreds of dollars for that prescription, or it’s not on formulary, it needs a prior authorization.
So, it’s really trying to avoid those disruptors and dissatisfaction elements that delay therapy by providing that information to the prescriber before they send that prescription out the door.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More